In stroke, other Treg-modulating therapies, including CD28 superagonist, IL-33, IL-2/IL-2-antibody complex, and adoptive Treg cell transfer, have been shown to increase peripheral Treg frequencies by two- to three-fold in young mice [58–61]. Here, IL2 is linked to stroke disorder.